Abiraterone vs Abiraterone Ashcure: Side-by-Side Comparison
Quick answer: Abiraterone and Abiraterone Ashcure are both androgen biosynthesis inhibitor (cyp17 inhibitor) used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Abiraterone | Abiraterone Ashcure |
|---|---|---|
| Drug class | Androgen biosynthesis inhibitor (CYP17 inhibitor) | Androgen biosynthesis inhibitor (CYP17 inhibitor) |
| ATC code | L02BX03 | L02BX03 |
| Primary indications | Metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer | Metastatic castration-resistant prostate cancer |
| Mechanism | Selectively inhibits CYP17A1 enzyme, blocking androgen biosynthesis in testes, adrenals, and prostate tumor tissue | Selectively inhibits CYP17A1 enzyme, blocking androgen biosynthesis in testes, adrenals, and prostate tumor tissue |
| Common dose | 1000 mg once daily with prednisone 5 mg twice daily | 1000 mg once daily with prednisone 5 mg twice daily |
| Detail page | Abiraterone details → | Abiraterone Ashcure details → |
How to choose between Abiraterone and Abiraterone Ashcure
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Androgen biosynthesis inhibitor (CYP17 inhibitor) on iMedic · Abiraterone full details · Abiraterone Ashcure full details
Frequently asked questions
Is Abiraterone better than Abiraterone Ashcure?
Neither is universally 'better.' They are both androgen biosynthesis inhibitor (cyp17 inhibitor) with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Abiraterone to Abiraterone Ashcure?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Abiraterone and Abiraterone Ashcure have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Abiraterone and Abiraterone Ashcure available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.